New Enterprise Associates related stories
All articles and analysis
Venture-backed Clementia raises $152 mln in Nasdaq debutMontréal biopharmaceutical company Clementia Pharmaceuticals Inc last week raised about $152 million (US$120 million) from its initial public offering on the Nasdaq Global Market. The news was noted by BDC Capital Healthcare Fund, an investor in Clementia since 2012. The company's other backers include Fonds de solidarité FTQ, Janus Henderson, OrbiMed Advisors and New Enterprise Associates. Clementia's IPO is the second completed this year by a Canadian life sciences company. In May, Vancouver's Zymeworks Inc secured about $86 million (US$64 million) /canada/2017/6/biotech-boom-continues-with-repares-90-mln-series-a-zymeworks-ipo/ from its Canadian and U.S. offering.
Fonds de solidarité FTQ discloses $13.4 mln Clementia financingFonds de solidarité FTQ has disclosed a March 2017 investment in Clementia Pharmaceuticals Inc, a Montréal clinical-stage biopharmaceutical company. The investment provided Clementia with about $13.4 million (US$10 million) in funding. Fonds de solidarité FTQ also said it is participating in the company's initial public offering, which was priced this week to raise as much as /canada/2017/8/vc-backed-4/ $172 million (US$138 million). Clementia, which was launched in 2010, is developing treatments for patients suffering from debilitating bone and other diseases.
VC-backed Clementia prices IPO to raise as much as $172 mlnMontréal clinical-stage biopharmaceutical company Clementia Pharmaceuticals Inc has priced its recently filed initial public offering on the Nasdaq Global Market. The company plans to sell up to 9.2 million common shares at US$15 per unit, which would generate proceeds of as much as $172 million (US$138 million). The issue is expected to close on August 7. Founded in 2010 by CEO Clarissa Desjardins, Clementia is developing treatments for patients suffering from debilitating bone and other diseases. It is backed by BDC Capital, Fonds de solidarité FTQ, Janus Henderson Investors, OrbiMed Advisors and New Enterprise Associates.
Amplyx Pharmaceuticals racks up $67 mln Series CSan Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $67 million in Series C financing. Sofinnova Venture Partners led the round with participation from other investors that included Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II and BioMed Ventures. In conjunction with the financing, Dr. Anand Mehra, managing partner at Sofinnova Ventures, and Dr. Johan Kördel, senior partner at Lundbeckfonden Ventures, will join the Amplyx board of directors.
- Elevation Innovation Partners collects $15 mln for maiden venture fund
Elevation Innovation Partners has raised $15 million for its debut venture fund. The fund is expected to close at $25 million by the end of the year. The pool will focus on fintech, enterprise software, marketing analytics and new media platform startups. The fund's investors include Mohandas Pai, former chief financial officer at Infosys and Jerry Rao, venture adviser to New Enterprise Associates.
- Juvo garners $40 mln Series B
Juvo, a provider of mobile identity scoring, has raised $40 million in Series B funding. New Enterprise Associates and Wing Venture Capital led the round with participation from other investors that included SignalFire. In conjunction with the funding, Peter Wagner, founding partner of Wing, will join Juvo’s board of directors.
- NEA leads Series A round for UnifyID
San Francisco-based UnifyID, an implicit authentication platform, has raised $20 million in Series A financing. New Enterprise Associates led the round with participation from return backers Andreessen Horowitz, Stanford-StartX and Accomplice Ventures. In addition to the funding, NEA General Partners Scott Sandell and Forest Baskett will join UnifyID's board.
